Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036250 | 1.00 | CYP2D6 (0.52) | CYP2D6GLSSRCLMNAMAPK1 | |
| Benzene SCHEMBL28174562 | 1.00 | CYP2D6 (0.52) | CYP2D6GLSSRCLMNAMAPK1 | |
| SCHEMBL18220934 | 1.00 | CYP2D6 (0.52) | CYP2D6GLSSRCLMNAMAPK1 | |
| SCHEMBL9530923 | 0.86 | GLS (0.46) | CYP2D6GLSSRCLMNAMAPK1 | |
| SCHEMBL11693823 | 0.84 | SRC (0.43) | CYP2D6GLSSRCKMT2AALDH1A1 | |
| SCHEMBL3298111 | 0.84 | GLS (0.45) | CYP2D6GLSSRCLMNAMAPK1 | |
| SCHEMBL9530930 | 0.84 | GLS (0.48) | CYP2D6GLSSRCLMNAMAPK1 | |
| SCHEMBL400208 | 0.84 | GLS (0.45) | CYP2D6GLSSRCLMNAMAPK1 | |
| SCHEMBL9248607 | 0.82 | ALDH1A1 (0.59) | CYP2D6GLSLMNAMAPK1KMT2A | |
| SCHEMBL19305342 | 0.82 | CYP2C19 (0.47) | CYP2D6SRCLMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8367826-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-02 | — | — | US | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1740591-B1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-4107431-A | ANTIBIOTICS | GLAXO LABORATORIES LIMITED (GB) | 1978-08-15 | — | — | US | disclosed |
| US-4103086-A | 8-Oxo-4-thia-1-azabicyclo (4.2.0)-oct-2-ene derivatives | SMITHKLINE CORPORATION (US) | 1978-07-25 | — | — | US | disclosed |
| US-4072674-A | FOR CEPHALOSPORIN CONGENERS | SMITHKLINE CORPORATION (US) | 1978-02-07 | — | — | US | disclosed |
| US-4045437-A | ANTIBACTERIAL | PFIZER, INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4045436-A | ANTIBACTERIAL | PFIZER INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4039532-A | BACTERICIDES | PFIZER INC. (US) | 1977-08-02 | — | — | US | disclosed |
| US-4039533-A | CEPHALOSPORINS | PFIZER INC. (US) | 1977-08-02 | — | — | US | disclosed |
| US-4006138-A | A CEPHALOSPORIN ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
| US-3966719-A | ANTIBACTERIAL | PFIZER INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3953436-A | 3,4-Dicarboxycephalosporins and derivatives | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CYP2D6 467/4885GLS 3661/4885SRC 299/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CYP2D6 467/4885GLS 3661/4885SRC 299/4885 |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | CYP2D6 467/4885GLS 3661/4885SRC 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.